Physician profile

Michaela Seigo

Internal Medicine · Newark, DE

NPI 1942731245

$826.08

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$411.68
Food and Beverage$322.58

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Olympus Corporation of The Americas $520.01 2023 Single Use Suction Valve (Sterile), Olympus
Astrazeneca Pharmaceuticals LP $128.00 2024 Fasenra
Takeda Pharmaceuticals U.S.A., INC. $58.44 2022-2024 Aralast
Jazz Pharmaceuticals INC. $53.08 2023 Xywav
Boehringer Ingelheim Pharmaceuticals, INC. $48.61 2022
Mylan Specialty L.P. $17.94 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michaela Seigo

$826.08

in general payments reported 2019-2025

Years
2022-2024
Top company
Olympus Corporation of The Americas

https://glasscript.com/doctor/8642526/michaela-seigo

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.